Crenezumab - Drugbank

1/9/2019 Crenezumab - DrugBank

Drugs

Crenezumab

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

IDENTIFICATION

Name Crenezumab

Accession Number DB11959

Type Biotech

Groups Investigational

Biologic Protein Based Therapies ClassiﬁcClass ation Monoclonal antibody (mAb)

Description Crenezumab has been used in trials studying the treatment of Alzheimer's Disease.

Protein chemical Not Available formula

Protein average Not Available weight

Sequences Not Available

Synonyms Not Available

External IDs MABT5102A

Categories Alzheimer Disease, drug therapy Blood Proteins Immunoproteins

Amino Acids, Peptides, and Globulins Proteins Proteins Immunoglobulins Serum Globulins Antibodies

UNII O8AS5277H0

CAS number 1095207-05-8

PHARMACOLOGY

Indication Not Available

Pharmacodynamics Not Available

Mechanism of Not Available action

Absorption Not Available https://www.drugbank.ca/drugs/DB11959 1/4 1/9/2019 Crenezumab - DrugBank

Volume of Not Available distribution Drugs Protein binding Not Available

Metabolism Not Available

Route of Not Available elimination

Half life Not Available

Clearance Not Available

Toxicity Not Available

Aﬀected organisms Not Available

Pathways Not Available

Pharmacogenomic Not Available Eﬀects/ADRs

INTERACTIONS

Drug Interactions ALL DRUGS APPROVED VET APPROVED NUTRACEUTICAL ILLICIT WITHDRAWN

INVESTIGATIONAL EXPERIMENTAL

Show 10 entries Search

DRUG ↑↓ INTERACTION ↑↓ Abciximab The risk or severity of adverse eﬀects can be increased when Abciximab is combined with Crenezumab.

Abituzumab The risk or severity of adverse eﬀects can be increased when Crenezumab is combined with Abituzumab.

Adalimumab The risk or severity of adverse eﬀects can be increased when Adalimumab is combined with Crenezumab.

Adecatumumab The risk or severity of adverse eﬀects can be increased when Adecatumumab is combined with Crenezumab.

Aducanumab The risk or severity of adverse eﬀects can be increased when Crenezumab is combined with Aducanumab.

Afelimomab The risk or severity of adverse eﬀects can be increased when Afelimomab is combined with Crenezumab.

Alemtuzumab The risk or severity of adverse eﬀects can be increased when Alemtuzumab is combined with Crenezumab.

Alirocumab The risk or severity of adverse eﬀects can be increased when Alirocumab is combined with Crenezumab.

Amatuximab The risk or severity of adverse eﬀects can be increased when Crenezumab is combined with Amatuximab.

AMG 108 The risk or severity of adverse eﬀects can be increased when AMG 108 is combined with Crenezumab.

Showing 1 to 10 of 244 entries ‹ 1 2 3 4 5 … 25 ›

Food Interactions Not Available

REFERENCES https://www.drugbank.ca/drugs/DB11959 2/4 1/9/2019 Crenezumab - DrugBank

General References Not Available

Drugs External Links PubChem Substance 347911262

Wikipedia Crenezumab

CLINICAL TRIALS

Clinical Trials Show 10 entries Search

PHASE ↑↓ STATUS ↑↓ PURPOSE ↑↓ CONDITIONS ↑↓ COUNT ↑↓ 1 Completed Treatment Healthy Volunteers 2

2 Active Not Recruiting Treatment Alzheimer's Disease (AD) 1

2 Completed Treatment Alzheimer's Disease (AD) 3

3 Active Not Recruiting Treatment Alzheimer's Disease (AD) 1

3 Recruiting Treatment Alzheimer's Disease (AD) 2

Showing 1 to 5 of 5 entries ‹ 1 ›

PHARMACOECONOMICS

Manufacturers Not Available

Packagers Not Available

Dosage forms Not Available

Prices Not Available

Patents Not Available

PROPERTIES

State Not Available

Experimental Not Available Properties

TAXONOMY

Description Not Available

Kingdom Organic Compounds

Super Class Organic Acids

Class Carboxylic Acids and Derivatives

Sub Class Amino Acids, Peptides, and Analogues

Direct Parent Peptides

Alternative Parents Not Available

Substituents Not Available

Molecular https://www.drugbank.ca/drugs/DB11959 3/4 1/9/2019 Crenezumab - DrugBank

Framework Not Available

External Not Available Drugs Descriptors

Drug created on October 20, 2016 15:05 / Updated on November 02, 2018 07:18

About Support Commercial Products About DrugBank FAQ API Pricing

DrugBank Blog Help This project is supportedAPI by tDocshe Canadian Institutes of Health Research (award #111062), Alberta Innovates - Health Solutions, and by The Wishart Research Group Email Support Data Licenses Metabolomics Innovation Centre (TMIC), a nationally-funded research Terms of Use and core facility that supSupportports a wide range of cutting-edge metabolomic studies. TMIC is funded by Genome Alberta, Genome Privacy Policy British Columbia, and Genome Canada, a not-for-proﬁt organization that is leading Canada's national genomics strategy with funding from the federal government. Maintenance, support, and commercial licensing is provided by OMx Personal Health Analytics, Inc. Designed by Educe Design & Innovation Inc.

https://www.drugbank.ca/drugs/DB11959 4/4